$0

Spotlight on Bayer’s and Takeda’s Cell Therapy Strategy Part I

As Bayer continues to invest and expand into the cell therapy space, the Celltelligence team provides an analysis below on Bayer’s possible strategy, manufacturing technology, and partnerships. In a subsequent part 2 blast, the Celltelligence team will provide a similar overview for Takeda, who appears to be pursuing a similar cell therapy approach.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.